Stopping Pharma’s Ripoffs and Drug Savings For All Act

This bill prevents drug companies from extending patent monopolies by presuming additional patents for the same drug expire when the first patent ends, unless the company proves they cover distinct inventions. It also requires the U.S. Patent Office to review its processes to stop issuing overlapping patents for the same drug or biological product, aiming to accelerate generic competition. The U.S. Patent and Trademark Office must report on these changes within one year of enactment. The bill directly affects pharmaceutical companies' patent strategies and could impact timelines for lower-cost generic drug availability.